LianBio (LIAN)
LianBio Statistics
Share Statistics
LianBio has 108.06M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 108.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 25.38M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | -% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -1.6 and the forward PE ratio is null.
| PE Ratio | -1.6 |
| Forward PE | null |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.68 |
| P/FCF Ratio | -1.75 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for LianBio.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.24, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.24 |
| Quick Ratio | 13.24 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.64 |
| Cash Flow / Debt | -22.86 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.42% and return on capital (ROIC) is -41.94%.
| Return on Equity (ROE) | -0.42% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -41.94% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -676.63K |
| Employee Count | 163 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -332.60K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -92.21% in the last 52 weeks. The beta is 0.23, so LianBio's price volatility has been higher than the market average.
| Beta | 0.23 |
| 52-Week Price Change | -92.21% |
| 50-Day Moving Average | 0.3 |
| 200-Day Moving Average | 2.54 |
| Relative Strength Index (RSI) | 41.97 |
| Average Volume (20 Days) | 959.84K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.00M |
| Operating Income | -125.35M |
| Net Income | -110.29M |
| EBITDA | -124.35M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.02 |
Balance Sheet
The company has 79.22M in cash and 4.34M in debt, giving a net cash position of 74.88M.
| Cash & Cash Equivalents | 79.22M |
| Total Debt | 4.34M |
| Net Cash | 74.88M |
| Retained Earnings | -470.52M |
| Total Assets | 262.90M |
| Working Capital | 232.18M |
Cash Flow
In the last 12 months, operating cash flow was -99.19M and capital expenditures -1.84M, giving a free cash flow of -101.03M.
| Operating Cash Flow | -99.19M |
| Capital Expenditures | -1.84M |
| Free Cash Flow | -101.03M |
| FCF Per Share | -0.94 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LIAN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -318.75% |
| FCF Yield | -293.08% |
Analyst Forecast
Currently there are no analyst rating for LIAN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -2.38 |
| Piotroski F-Score | 2 |